Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006390 · ClinicalTrials.gov registry record · Phase 2
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006390 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00006390, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Combining monoclonal antibody therapy, chemotherapy, radiation therapy, and peripheral stem cell transplantation may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of alemtuzumab plus peripheral stem cell transplantation in treating patients who have chronic lymphocytic leukemia.
Interventions
- DRUG cyclophosphamide
- RADIATION radiation therapy
- BIOLOGICAL alemtuzumab
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006390
The ClinicalTrials.gov registry entry for NCT00006390 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00006390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006390 about?
NCT00006390 is a clinical study titled "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia". RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy...
What is the current status of trial NCT00006390?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-07-05.
What interventions are being tested in trial NCT00006390?
The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), alemtuzumab (BIOLOGICAL), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006390?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.